BioHorizons has added Prolifica, a new allogeneic growth factor technology, to its biomaterials portfolio to support bone healing and tissue regeneration. The naturally occurring blend of growth factors is unique in the dental market for preserving a natural biphasic release of proteins, delivering an initial surge to trigger the healing cascade followed by a sustained release for continued regenerative support, according to a press release from the company.
Prolifica retains a minimum of 16 unique proteins associated with cell growth, division, and the biological processes involved in bone healing and tissue regeneration. Clinicians can use it in stand-alone bone grafting procedures or in combination with autologous bone or other allograft materials.
Steve Boggan, president and CEO of BioHorizons, said the product responds to demand for advanced allograft solutions as complex hard tissue regenerative procedures become more common with an aging population. Jason Cordell, senior director of biomaterials, said Prolifica is processed to maintain a high concentration of growth factors, calling it one of the newest processes available on the market.
The comments and observations expressed herein do not necessarily reflect the opinions of DrBicuspid.com, nor should they be construed as an endorsement or admonishment of any particular idea, vendor, or organization. Some content may be AI-generated.
